caa a22 4500 47581892X CHVBK 20180406123817.0 cr unu---uuuuu 170329e20000801xx s 000 0 eng 10.1007/s002280000158 doi (NATIONALLICENCE)springer-10.1007/s002280000158 Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen [Elektronische Daten] [M. Zoppi, S. Braunschweig, U. P. Kuenzi, R. Maibach, R. Hoigné] Objectives: Realising the limitations of spontaneous drug monitoring systems concerning the epidemiological aspects, a comprehensive program was founded. It was based on previous publications from the US, Canada and Northern Ireland, mainly those of the BCDSP (Boston Collaborative Drug Surveillance Programme). Methods: Drug monitoring was carried out by a group of physicians which included the medical head of each of the divisions of internal medicine, a statistician and an informatician. Only probable or definite drug event relationships were included. A probable event is defined as one in which the drug interaction was more likely to be the cause than any non-drug-related cause. The same criteria were valid for the lethal reactions. Results: In the present evaluation, we found 26 probable lethal adverse drug reactions out of a total of 48,005 patients consecutively admitted to the divisions of internal medicine of three Swiss teaching hospitals during the years 1974-1993, an incidence of 0.054%. The median age of the cohort was 68 years (range 11-103 years), of which 49% were women. The median hospital stay was 14 days and the median number of drugs was eight per patient. Conclusion: The patients with a lethal outcome were presented under the eight pharmacologic-therapeutic classes of drugs and the classification proposed by NS Irey. This is based on long histopathologic experience and helps to identify preventable risks. Springer-Verlag Berlin Heidelberg, 2000 Key words Lethal ADRs nationallicence Pharmacologic-therapeutic groups of drugs nationallicence Classification of ADRs by NS Irey nationallicence Zoppi M. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut Braunschweig S. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut Kuenzi U. P. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut Maibach R. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut Hoigné R. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut https://doi.org/10.1007/s002280000158 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280000158 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zoppi M. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut NATIONALLICENCE 700 1- Braunschweig S. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut NATIONALLICENCE 700 1- Kuenzi U. P. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut NATIONALLICENCE 700 1- Maibach R. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut NATIONALLICENCE 700 1- Hoigné R. Swiss foundation "Comprehensive Hospital Drug Monitoring”, Berne/St. Gallen, Switzerland, CH aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer